The human CCK-BR has been shown to be upregulated in pancreatic cancer compared with normal tissues (41) . The human pancreas produces gastrin during fetal development, after which gastrin expression is downregulated, and no gastrin can be detected in the healthy adult pancreas. However, gastrin is reexpressed in pancreatic tumors where it enhances proliferation through an autocrine mechanism (44) . Evidence that both the receptor and ligand become upregulated in pancreatic cancer suggest it may be an important pathway involved in pancreatic cancer development and growth. Previous work has shown that stable, long-term reduction in gastrin expression through RNA interference (RNAi) techniques significantly reduces pancreatic tumor growth and metastasis in vivo (27) . CCK is a ligand for both the CCK-BR and CCK-A receptor (AR), and is also reexpressed by pancreatic tumors. However, RNAi downregulation of endogenous CCK had virtually no effect on human pancreatic tumor growth (28) , suggesting that the CCK-BR interaction with gastrin is the important mediator of growth in gastrointestinal malignancies.
The CCK-BR has also been reported to play an important role in carcinogenesis. Ectopic expression of the CCK-BR in a nontumorigenic, gastrin-producing colon epithelial cell line was sufficient to transform these cells into tumorigenic cells (9) . Additional evidence of the CCK-BR's contribution to carcinogenesis is supported by studies involving transgenic mice (12, 21, 38) . Transgenic expression of the CCK-BR in murine pancreatic acinar cells results in increased pancreas growth, transdifferentiation of acinar cells into ductal structures, and development of pancreatic cancer (12) . Although overexpression of progastrin in mice induces hyperproliferation of the colon and promotes colorectal cancer (38) , mice carrying CCK-BR knockout alleles have reduced gastrin-dependent colonic proliferation, fewer aberrant crypt foci, and decreased tumor size (21) . Furthermore, while progastrin may play an important role in proliferation and colon carcinogenesis through its actions at the annexin A 2 receptor (36), gastrin-17 is the major form of gastrin involved in pancreatic cancer growth (28, 44) .
Binding of gastrin to CCK-BR activates a diverse group of intracellular signaling pathways (1, 18) . In the rat exocrine pancreatic cell line AR42J, gastrin stimulation activates protein kinase B (Akt), which promotes survival by phosphorylating the proapoptotic protein BAD (33, 47) . Similarly, Akt is phosphorylated in response to gastrin stimulation in human esophageal cancer cells (20) . Stimulation of gastric epithelial cells with gastrin upregulates expression of the anti-apoptotic proteins Bcl-2 and survivin (22) . The mitogen-activated protein kinase and Akt pathways also are involved in gastrin-induced cyclooxygenase-2 expression in colon cancer cells (13) . In another gastrointestinal malignancy, gastric cancer, downregulation of the CCK-BR in cell lines increased caspase-3 expression and apoptosis (52) . It was hypothesized that, since growth of pancreatic cancer cells is regulated by the interaction of gastrin with the CCK-BR, downregulation of the CCK-BR will inhibit pancreatic cancer growth and promote apoptosis. In this study, we examined the effects of downregulation of the CCK-BR on proliferation and apoptosis in human pancreatic cancer cells.
MATERIALS AND METHODS
Cell lines. Human pancreatic cancer cell lines AsPC-1, MIA PaCa-2 , and PANC-1 were purchased from the ATCC (Rockville, MD) and were maintained in appropriate media with 10% FBS (Invitrogen, Carlsbad, CA). In a previous study, a panel of human pancreatic cancer cell lines was evaluated for CCK-BR mRNA expression by real-time RT-PCR (28), and PANC-1 cancer cells were found to express the most CCK-BR mRNA. Therefore, further studies establishing stable clones with short-hairpin RNA (shRNA) transfection were done using PANC-1 cancer cells.
Inhibition of CCK-BR with RNAi. Two independent CCK-BRspecific stealth small-interfering RNAs (siRNAs) [HSS189635, si849 (CCGUACUGCUGCUUCUGGUCUUGUU) and HSS141489, si564 (CCGUCAUCUGCAAGGGGGUUUCCUA)] and control siRNA (Medium GC Duplex no. 2, no. 12935-112) were obtained from Invitrogen. In addition, two independent shRNAs that targeted different regions of CCK-BR mRNA were selected based upon RNA secondary structure. The shRNA duplexes started at the following base locations in the CCK-BR RNA: GenBank no. AF441129, sites sh377 (CTGCAAGGCGGTTCCTAC) and sh1413 (GAAACTT-GCGCTCGCTGC) (Oligoengine, Seattle, WA). A nonspecific shRNA control (NSC) containing a shRNA oligonucleotide duplex with no known homology to any mammalian gene sequence was used as a negative control. Each shRNA duplex was cloned into the pSuper.hygro vector, and shRNA-containing plasmids were verified by DNA sequence analysis.
For the RNAi experiments, AsPC-1, MIA PaCa-2, or PANC-1 cells were transfected with CCK-BR siRNAs with Lipofectamine 2000 (Invitrogen). RNA was isolated after 48 h to evaluate mRNA downregulation. Stable PANC-1 CCK-BR shRNA-expressing clones were transfected and selected by hygromycin resistance. CCK-BR mRNA knockdown in shRNA-transfected clones was verified by real-time RT-PCR as described below.
Real-time RT-PCR analysis. RNA was extracted using an RNAeasy kit (Qiagen, Valencia, CA), and cDNA was produced using the High-Capacity cDNA Reverse Transcriptase Kit (ABI, Carlsbad, CA) with 2 g of RNA per reaction. Real-time PCR was carried out with 200 ng of cDNA per reaction using ABI Taqman master mix and CCK-BR primers (HS00176123_m1) or CCK-A receptor primers (HS00167891_m1) with cyclophilin A (HS99999904_m1) as the internal control. All reactions were performed in quadruplicate. PCR amplification and analysis were done with the Applied Biosystems Sequence Detection System 7900 HT using the Relative Quantification (ddCt) Plate setup. RNA levels are calculated from the mean relative quantity (RQ ϭ 2 Ϫ⌬⌬CT ) with a 95% confidence interval [CI; RQ ϭ 2 Ϫ(⌬⌬CT Ϯ CI) ]. Receptor binding assays. Pancreatic cancer cells (wild-type, nonspecific control clones, and CCK-BR shRNA clones) were grown to log phase. Cells were washed two times in 0.154 M NaCl, scraped with a rubber policeman, and centrifuged at 1,800 g for 10 min at 4°C. The cell pellet was resuspended in 50 mM Tris·HCl, pH 7.4, with 0.1 mM bacitracin and 1 tablet of Complete, mini, EDTA-free Protease Inhibitor Cocktail protease inhibitor cocktail/50 ml buffer (Roche, Indianapolis, IN). Cells were homogenized with a Brinkman Polytron and then centrifuged at 48,000 g for 30 min at 4°C to pellet cell membranes, and the membrane fraction was resuspended in an incubation buffer previously described (42) containing 0.1% BSA. Homogenates (total protein 200 -400 g/ml) were reacted with 125 Ilabeled gastrin (Perkin Elmer, Billerica, MA) for 60 min at 4°C, and the reaction was terminated by rapid filtration through Whatman GF/B filters with a Brandel harvester. Nonspecific binding was evaluated using 1 M of unlabeled gastrin (Peninsula Laboratories, Carlsbad, CA). Radioactivity was assessed on a gamma scintillation counter with 80% efficiency, and receptor binding capacity (B max) was determined by using Prism Software (Graphpad). Each assay was performed in duplicate, and each sample was done in duplicate or triplicate.
Cell growth evaluation and bromodeoxyuridine assay. PANC-1 cells were seeded onto a 12-well plate at a density of 30,000 cells/ well. On the following day, cells were transfected with vehicle (Lipofectamine 2000), control siRNA, or CCK-BR siRNA. Each day following transfection, cell growth was evaluated by staining cells with trypan blue and counting viable cells on a hemocytometer. For proliferation assays, AsPC-1, MIA PaCa-2, and PANC-1 cells were seeded on a 96-well plate at a density of 2,500 cells/well and cultured for 72 h. CellTiter 96 Aqueous One Solution, an 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay reagent (Promega, Madison, WI), was added to each well, plates were incubated at 37°C for 1 h, and absorbance was read at 490 nm. Bromodeoxyuridine (BrdU) incorporation was measured using a colorimetric enzyme-linked immunosorbent assay-based kit (Roche). Transfected cells were incubated with BrdU for the last 16 h of the 72-h treatment with siRNA, and BrdU incorporation was assessed as described in the manufacturer's protocol.
Cell cycle analysis. For cell cycle analysis, PANC-1 cells were transfected with CCK-BR siRNA or control siRNA, and, after 72 h, cells were fixed in 75% ethanol. Cells were then stained with 50 g/l of propidium iodide and treated with 1 g/l of RNase A. Control siRNA and CCK-BR siRNA samples were run on the FACSCalibur flow cytometer (BD Biosciences, San Diego, CA), and data were analyzed with Cellquest (Verity Software, Topsham, ME).
Apoptosis assays. Caspase-3 activity was measured using the Colorimetric CaspACE Assay (Promega). Seventy-two hours after transfection with siRNA, PANC-1 cells were collected, resuspended in cell lysis buffer at a concentration of 10 8 cells/ml, and lysed by freezethaw. The assay was performed as described in the manufacturer's protocol using 150 g of protein/sample. Apoptotic cells were detected using the APO-BrdU TUNEL assay kit (Invitrogen). Briefly, PANC-1 cells were collected 96 h after transfection with siRNA and immediately fixed in 1% paraformaldehyde. Cells were incubated in a DNA-labeling solution (TdT and BrdUTP) for 3 h at 37°C, washed, and incubated with anti-BrdU Alexa Fluor 488-labeled antibody for 30 min at room temperature. Samples were immediately analyzed by flow cytometry.
Protein extraction and western blot analysis. Protein for Western blots was harvested 72 h after transfection with siRNA. Total protein was determined using a MicroBCA assay (Pierce/Thermo Fisher Scientific, Rockford, IL). Whole cell lysates (50 g of protein/well) were mixed with Laemmli's reducing sample buffer, resolved by SDS-PAGE, and electrophoretically transferred to 0.2-m nitrocellulose membranes. Blots were blocked in 3% nonfat dry milk or 3% ovalbumin (A7641; Sigma, St. Louis, MO) and incubated overnight (4°C) with primary antibodies. Antibodies and titers used were as follows: phosphorylated-Akt (Ser 473 ) 1:1,000 (no. 4060; Cell Signaling Technology, Danvers, MA), Akt (pan) 1:2,000 (no. 4691; Cell Signaling Technology), X-linked inhibitor of apoptosis protein (XIAP) 1:1,000 (no. 610716; BD Biosciences), and ␤-actin 1:10,000 (A2228; Sigma). The blots were washed and probed with speciesspecific secondary antibodies coupled to horseradish peroxidase (Am-ersham, Piscataway, NJ), and the signal was detected using an enhanced chemiluminescence substrate (Pierce/Thermo Fisher Scientific).
Migration assay. Pancreatic cancer cells (wild-type, nonspecific control clones, and CCK-BR shRNA clones) were seeded on 12-well plates and allowed to grow to confluency. A scratch in the monolayer was created with a 200-l pipet tip. Phase-contrast (CKX41; Olympus, Tokyo, Japan) photographs were taken immediately following the scratch (0 h) and 24 h after the scratch. Scratch width was measured using Axio Vision (Carl Zeiss MicroImaging) software, and the percentage of the scratch area closed was calculated as (width at 0 h Ϫ width at 24 h)/width at 0 h. Results were standardized to wild type.
Statistics. Results are expressed as means Ϯ SE. Statistical comparisons were made using the two-tailed Student's t-test. A P value of Ͻ0.05 was considered to be statistically significant, and a modified Bonferroni method was used to correct for multiple comparisons. For the real-time data, pairwise Student's t-tests were performed on the normalized mean ⌬C T values for each group.
RESULTS

CCK-BR RNAi effectively decreases receptor expression.
Two CCK-BR-specific siRNAs (targeted to different regions of CCK-BR mRNA) were tested for their ability to downregulate the receptor in PANC-1 cells. Both siRNAs, si564 and si849, were effective in decreasing CCK-BR mRNA as demonstrated by real-time RT-PCR (Fig. 1A) . Because CCK-BR si849 was highly effective in downregulating CCK-BR expression in PANC-1 cells Ͼ90%, si849 was used to downregulate CCK-BR in all subsequent siRNA experiments. The CCK-BR siRNA (si849)-transfected cells did not have altered expression of the CCK-AR (Fig. 1B) , indicating the specificity of this siRNA for the CCK-BR. Similarly, CCK-BR mRNA expression was decreased in PANC-1 cells stably transfected with the sh377 or sh1413 construct (Fig. 1C) . Although si849, sh377, and sh1413 each target separate regions of the CCK-BR mRNA, all were highly effective in knocking down CCK-BR mRNA. The CCK-BR mRNA was also decreased in siRNA-treated AsPC-1 and MIA PaCa-2 cancer cells (data not shown).
To confirm that the downregulation of the CCK-BR mRNA resulted in decreased receptor protein, receptor-binding assays were performed on the PANC-1 CCK-BR shRNA clones, NSCs, and wild-type cells with 125 I-labeled gastrin-17. Receptor binding affinity was in the nanomolar range, comparable with the physiological range previously determined to stimulate growth (44) . There was no difference in receptor number of the wild-type cells compared with the PANC-1 nonspecific control shRNA clones (Fig. 1D) . The B max was significantly decreased by 73 and 71%, respectively, in sh377 and sh1413 clones compared with wild-type and nonspecific control clones.
Downregulation of the CCK-BR decreases proliferation. At 72 h after transfection, CCK-BR siRNA-treated PANC-1 cells displayed a significant decrease in cell number. Growth of CCK-BR siRNA-treated PANC-1 cells was reduced by 73% compared with cells treated with control siRNA and by 69% compared with vehicle-treated cells (P Ͻ 0.001, Fig. 2A) . A decrease in cell viability was also seen in both (sh377 and sh1413) stable CCK-BR shRNA clones compared with wildtype and nonspecific control shRNA cells (Fig. 2B) as measured by the MTS cell proliferation assay. The decrease in cell growth upon downregulation of the CCK-BR suggests that CCK-BR inactivation may block DNA synthesis, and this finding was confirmed by BrdU labeling (Fig. 2C) in three pancreatic cancer cell lines, AsPC-1, MIA PaCa-2, and PANC-1. All cancer cell lines treated with siRNA CCK-BR had decreased BrdU incorporation compared with control siRNA-treated cells and vehicle-treated cells. CCK-BR sh377 clones and sh1413 clones had significantly less BrdU incorporation compared with wild-type and nonspecific control clones (P Ͻ 0.001; Fig. 2D ). These findings support the relationship between the CCK-BR and proliferation in pancreatic cancer.
Downregulation of the CCK-BR inhibits G 1 /S progression.
Cell cycle analysis performed on cells with downregulation of the CCK-BR confirmed the reduction in DNA synthesis and cell growth observed in CCK-BR siRNA-transfected PANC-1 cells. CCK-BR siRNA-treated PANC-1 cells had a 36% increase in cells residing in G 1 /G 0 phase compared with control siRNA-transfected cells (Fig. 3) . Correspondingly, CCK-BR downregulation led to 69% fewer cells in G 2 phase and 19% fewer cells in S phase compared with control siRNA (Fig. 3) . Taken together, these data indicate that downregulation of the CCK-BR results in an inhibition of G 1 /S progression.
Alteration of apoptotic markers with downregulation of the CCK-BR. Although downregulation of the CCK-BR inhibits proliferation, is it sufficient to promote apoptosis? To answer this question, several markers of apoptosis were analyzed in PANC-1 cells with downregulation of the CCK-BR either by siRNA or shRNA. CCK-BR downregulation resulted in an increase in caspase-3 activity compared with vehicle and control siRNA-treated cells (P Ͻ 0.001, Fig. 4A ). Similar results were observed with the CCK-BR shRNA clones, where all sh377 and sh1413 clones had higher capase-3 activity than untransfected cells or NSC clones (P Ͻ 0.001, Fig. 4B ). In addition to increased caspase-3 activity, the effect of downregulation of CCK-BR on the apoptotic cell population was confirmed by TUNEL assay. PANC-1 cells treated with CCK-BR siRNA displayed a significant increase in TUNELpositive cells compared with control siRNA-treated cells (P Ͻ 0.005, Fig. 4C ).
Expression of XIAP is known to be upregulated in pancreatic cancer (25, 37, 37) . XIAP binds to active caspase-3 (15, 16) and blocks the increased capase-3 activity induced during apoptosis. XIAP expression in CCK-BR siRNA-treated cells and CCK-BR shRNA clones was examined. After downregulation of the CCK-BR with siRNA in AsPC-1, MIA PaCa-2, and PANC-1 cells, XIAP expression was significantly lower than in control siRNA-and vehicle-treated cells (P Ͻ 0.05, Fig. 5A ). The reduction in XIAP expression also occurred in the CCK-BR shRNA clones. XIAP levels were reduced in both shRNA 377 and shRNA 1413 clones compared with wild-type and NSC clones (P Ͻ 0.05, Fig. 5B) .
Downregulation of the CCK-BR decreases Akt phosphorylation and migration.
The prosurvival signaling protein Akt is known to be phosphorylated and activated as a result of normal interaction of gastrin with the CCK-BR (47) . Akt phosphorylation leads to increased XIAP levels by blocking ubiquitination and proteasomal degradation of XIAP (14) . Because downregulation of the CCK-BR drastically reduces XIAP levels, we would predict that downregulation of CCK-BR would also cause a reduction in Akt phosphorylation. Although total Akt levels were unchanged in CCK-BR siRNA-treated cells, Akt phosphorylation at Ser 473 , which is important for the activation of Akt, was significantly decreased by CCK-BR siRNA treatment in AsPC-1, MIA PaCa-2, and PANC-1 cells (P Ͻ 0.05, Fig. 6 ).
Because the phosphatidylinositol 3-kinase (PI3K) pathway and Akt phosphorylation are known to mediate cell migration (4), scratch-wound assays were performed to assess cell migration in response to downregulation of the CCK-BR. Compared with untransfected wild-type cells or NSC clones, both CCK-BR shRNA clones demonstrated a decrease in migration (P Ͻ 0.005, Fig. 7 ).
DISCUSSION
The present study demonstrates that the CCK-BR is a potential target for developing novel strategies for the treat- In addition to decreasing cellular proliferation, G 1 /S progression is inhibited with downregulation of the CCK-BR, suggesting that downregulating this receptor induces cell cycle arrest. Cyclins that control G 1 /S transition have been found to be influenced by gastrin. Gastrin increases transcription of cyclin D1, D3, and E in a human gastric adenocarcinoma cell line and Swiss 3T3 cells that express the CCK-BR (31, 53). Therefore, it is possible that downregulation of the CCK-BR The increase in caspase-3 activity in PANC-1 cells treated with CCK-BR siRNA or in cells with stable shRNAmediated downregulation of CCK-BR is consistent with other studies (27, 52) . Herein, our results demonstrated for the first time that XIAP expression is decreased when the CCK-BR is downregulated. Many pancreatic cancer cell lines exhibit constitutive activation of Akt mediated through dysregulated phosphatase and tensin homolog (PTEN) expression (2, 3) . Gastrin stimulation activates Akt phosphorylation through the CCK-BR (47) , and this study demonstrates that downregulation of the CCK-BR in PANC-1 cells inhibits phosphorylation of Akt. Activated Akt is known to regulate XIAP by phosphorylation at Ser 87 . Phosphorylation of XIAP by Akt protects XIAP against ubiquitination and proteasomal degradation (14) . The decrease in XIAP expression observed upon CCK-BR downregulation is consistent with the decrease in activated Akt brought on by the CCK-BR siRNA treatment.
Akt, an integral part of the PI3K pathway, is involved in mediation of cell migration. We demonstrated that CCK-BR downregulation inhibits Akt phosphorylation and cell migration. Others have demonstrated that signaling pathways activated by the CCK-BR can regulate cellular adhesion by gastrin-induced modifications of p120, ␣-and ␤-catenins, and E-cadherin in intestinal epithelial cells (19) . More recently, in pancreatic cancer cells, the CCK-BR has been shown to regulate ␤ 1 -and ␣ v -integrins, which are involved in modulation of cell adhesion via the PI3K pathway (7, 8) .
Gemcitabine, the current standard of care treatment for pancreatic cancer, offers a low response rate, and only increases survival time by a mean of six months. Given alone, most therapeutic agents that target cancer cell-signaling pathways, particularly tyrosine kinase receptor-signaling pathways, are not effective in decreasing pancreatic tumor growth and metastasis (32) . Even small molecule inhibitors of the PI3K/ Akt pathway have failed to demonstrate efficacy in clinical trials with pancreatic cancer patients (34) . Unfortunately, the approach of "one size fits all" has not been effective in treating pancreatic cancer. Recently, a set of genes identified as "driver genes" have been described in pancreatic cancer (23) . Among these, Carter et al. (6) describe a PI3K suppressor gene SNP (PIK3CG/R839C), which has the second highest scoring predicted driver mutation among these genes in pancreatic cancer. Because PI3K␥ transmits signals downstream from G proteincoupled receptors, Korc (23) suggested that there may be a connection between mutations in PIK3CG and activation of the CCK-BR. Knowing this is a key pathway in pancreatic cancer growth, interruption of the CCK-BR signaling pathway may lead to advances in the treatment of pancreatic cancer. Therapies directed toward Kras, another driver mutation, which is mutated early on in the development of pancreatic cancer in the precursor pancreatic intraepithelial neoplasms lesions, have not improved survival (26) , suggesting that Kras alone is not controlling growth of pancreatic cancer. Moreover, recent studies suggest that G protein-coupled receptor signaling systems play a critical role in mitogenic signaling and are implicated in the growth of multiple solid tumors, including the pancreas (35, 51) . Because the CCK-BR promotes growth primarily in gastrointestinal cancers like pancreatic cancer and downregulation of the CCK-BR blocks pancreatic cancer cell growth, targeting the CCK-BR as a possible pancreatic cancer therapy is promising.
Although many CCK-BR antagonists have been identified, there are no drugs targeting the CCK-BR in clinical use because of their poor biodistribution and pharmacokinetics (5).
Two pharmacological agents that target the CCK-BR have been evaluated in clinical trials for treatment of pancreatic cancer. The first compound, gastrazole, is a high-affinity CCK-BR antagonist. When compared with placebo, pancreatic cancer patients treated with gastrazole showed a slight increase in survival (10) . Unfortunately, the very low oral bioavailability of gastrazole required that the drug be administered intravenously. Z-360, a more recently developed orally active CCK-BR antagonist, was evaluated in phase Ib/IIa clinical trials in combination with gemcitabine (30) . Although a trend toward reduced pain and increased survival were observed, these differences were not statistically significant. However, in both trials that compared CCK-BR antagonists with conventional therapeutics, Z-360 and gastrazole had low toxicity and high tolerability. The results of tolerability of these drugs agree with previous work where the CCK-BR was knocked out in mice.
Although the potential for CCK-BR-targeted therapies is evident, the current pharmacological antagonists for the CCK-BR are inadequate. The development of an RNAi-based approach to selectively downregulate CCK-BR expression holds promise for a more efficient therapy. Previous work examining CCK-BR knockout mice demonstrated that these animals had few phenotypic differences from wild-type mice. CCK-BR-deficient mice had increased gastric pH, more G cells, and a decrease in the thickness of the oxyntic mucosa of the stomach (11, 24) . Evidence from the CCK-BR knockout mouse model and the CCK-BR antagonist clinical trials supports the idea that targeting the CCK-BR as a therapeutic strategy can be effective and well tolerated. Our current studies indicate that the development of targeted therapeutics against the CCK-BR, including RNAi-based therapies, for pancreatic cancers and for other gastrin-dependent malignancies will be an important new direction in treating these diseases.
